BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34777375)

  • 21. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
    Seo SH; Jin HT; Park SH; Youn JI; Sung YC
    Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In silico/In vivo analysis of high-risk papillomavirus L1 and L2 conserved sequences for development of cross-subtype prophylactic vaccine.
    Namvar A; Bolhassani A; Javadi G; Noormohammadi Z
    Sci Rep; 2019 Oct; 9(1):15225. PubMed ID: 31645650
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical study of safety and immunogenicity of combined rubella and human papillomavirus vaccines: Towards enhancing vaccination uptake rates in developing countries.
    Gohar A; Abdeltawab NF; Shehata N; Amin MA
    Papillomavirus Res; 2019 Dec; 8():100172. PubMed ID: 31185296
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rational design of a triple-type human papillomavirus vaccine by compromising viral-type specificity.
    Li Z; Song S; He M; Wang D; Shi J; Liu X; Li Y; Chi X; Wei S; Yang Y; Wang Z; Li J; Qian H; Yu H; Zheng Q; Yan X; Zhao Q; Zhang J; Gu Y; Li S; Xia N
    Nat Commun; 2018 Dec; 9(1):5360. PubMed ID: 30560935
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Papillomavirus vaccines.
    Duggan-Keen MF; Brown MD; Stacey SN; Stern PL
    Front Biosci; 1998 Dec; 3():D1192-208. PubMed ID: 9835649
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of six cell penetrating peptides with different properties for in vitro and in vivo delivery of HPV16 E7 antigen in therapeutic vaccines.
    Shahbazi S; Bolhassani A
    Int Immunopharmacol; 2018 Sep; 62():170-180. PubMed ID: 30015237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention and treatment of cervical cancer by a single administration of human papillomavirus peptide vaccine with CpG oligodeoxynucleotides as an adjuvant in vivo.
    Yang Y; Che Y; Zhao Y; Wang X
    Int Immunopharmacol; 2019 Apr; 69():279-288. PubMed ID: 30743204
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunohistochemical characterization of integrin alfa 6 in uterus and cervix of the cynomolgus monkeys (Macaca fascicularis) with MfPV3 infection.
    Setyawaty D; Mariya S; Prabandari SA; Boilessen DR; Holst PJ; Darusman HS
    J Med Primatol; 2024 Feb; 53(1):e12690. PubMed ID: 38345331
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive.
    Muderspach L; Wilczynski S; Roman L; Bade L; Felix J; Small LA; Kast WM; Fascio G; Marty V; Weber J
    Clin Cancer Res; 2000 Sep; 6(9):3406-16. PubMed ID: 10999722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel HPV prophylactic peptide vaccine, designed by immunoinformatics and structural vaccinology approaches.
    Negahdaripour M; Eslami M; Nezafat N; Hajighahramani N; Ghoshoon MB; Shoolian E; Dehshahri A; Erfani N; Morowvat MH; Ghasemi Y
    Infect Genet Evol; 2017 Oct; 54():402-416. PubMed ID: 28780192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunization with Human Papillomavirus 16 L1+E2 Chimeric Capsomers Elicits Cellular Immune Response and Antitumor Activity in a Mouse Model.
    López-Toledo G; Schädlich L; Alonso-Castro ÁJ; Monroy-García A; García-Rocha R; Guido MC; Gissmann L; García-Carrancá A
    Viral Immunol; 2016 Jun; 29(5):276-87. PubMed ID: 27058179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In Silico Design and Immunological Studies of Two Novel Multiepitope DNA-Based Vaccine Candidates Against High-Risk Human Papillomaviruses.
    Kayyal M; Bolhassani A; Noormohammadi Z; Sadeghizadeh M
    Mol Biotechnol; 2021 Dec; 63(12):1192-1222. PubMed ID: 34308516
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.
    Esquerré M; Momot M; Goubier A; Gonindard C; Leung-Theung-Long S; Misseri Y; Bissery MC
    Vaccine; 2017 Mar; 35(11):1509-1516. PubMed ID: 28196735
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Viral recombinant vaccines to the E6 and E7 antigens of HPV-16.
    He Z; Wlazlo AP; Kowalczyk DW; Cheng J; Xiang ZQ; Giles-Davis W; Ertl HC
    Virology; 2000 Apr; 270(1):146-61. PubMed ID: 10772987
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine.
    Smalley Rumfield C; Pellom ST; Morillon Ii YM; Schlom J; Jochems C
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554612
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.
    Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM
    Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides.
    Zwaveling S; Ferreira Mota SC; Nouta J; Johnson M; Lipford GB; Offringa R; van der Burg SH; Melief CJ
    J Immunol; 2002 Jul; 169(1):350-8. PubMed ID: 12077264
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model.
    Sharma RK; Srivastava AK; Yolcu ES; MacLeod KJ; Schabowsky RH; Madireddi S; Shirwan H
    Vaccine; 2010 Aug; 28(36):5794-802. PubMed ID: 20603135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.
    Van Damme P; Leroux-Roels G; Simon P; Foidart JM; Donders G; Hoppenbrouwers K; Levin M; Tibaldi F; Poncelet S; Moris P; Dessy F; Giannini SL; Descamps D; Dubin G
    Vaccine; 2014 Jun; 32(29):3694-705. PubMed ID: 24674663
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A multi-genotype therapeutic human papillomavirus vaccine elicits potent T cell responses to conserved regions of early proteins.
    Hancock G; Blight J; Lopez-Camacho C; Kopycinski J; Pocock M; Byrne W; Price MJ; Kemlo P; Evans RI; Bloss A; Saunders K; Kirton R; Andersson M; Hellner K; Reyes-Sandoval A; Dorrell L
    Sci Rep; 2019 Dec; 9(1):18713. PubMed ID: 31822717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.